CEACAM5 and non-small cell lung carcinoma: As shown in Figure 4, after treatment with Afatinib, the protein expressions of CEA, CA125, and CY-FRA21-1 in NSCLC cells were lower than that in DDP+PEM and saline groups, indicating that Afatinib can reduce the expressions of tumor markers, inhibit the growth of tumors, and improve the health status of patients with NSCLC.